<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255684</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000448637</org_study_id>
    <secondary_id>URCC-U19403</secondary_id>
    <secondary_id>URCC-RSRB-10063</secondary_id>
    <nct_id>NCT00255684</nct_id>
  </id_info>
  <brief_title>Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer</brief_title>
  <official_title>Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and
      radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the
      growth of cancer cells. It also stops the patient's immune system from rejecting the donor's
      stem cells. The donated stem cells may replace the patient's immune system and help destroy
      any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from
      a donor can also make an immune response against the body's normal cells. Giving cyclosporine
      and mycophenolate mofetil after transplant may stop this from happening.

      PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide
      together with total-body irradiation followed by cyclosporine and mycophenolate mofetil works
      in treating patients who are undergoing a donor umbilical cord blood transplant for
      hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the frequency, extent, and rate of donor (myeloid and lymphoid) engraftment in
           patients with serious hematologic malignancies treated with nonmyeloablative
           conditioning regimen comprising fludarabine, cyclophosphamide, and low-dose total-body
           irradiation followed by unrelated allogeneic umbilical cord blood transplantation and
           post-transplant immunosuppression comprising cyclosporine and mycophenolate mofetil.

        -  Correlate clinical and umbilical cord blood-related factors with engraftment in patients
           treated with this regimen.

        -  Determine transplant-related complications, in terms of toxicity, myelosuppression,
           infections, and acute and chronic graft-versus-host disease, in patients treated with
           this regimen.

        -  Determine disease-free and overall survival of patients treated with this regimen.

        -  Determine treatment-related mortality of patients treated with this regimen.

      OUTLINE: This is a uncontrolled, pilot study.

        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine IV over 30 minutes
           daily on days -6 to -2 and cyclophosphamide IV over 2 hours on day -6 and undergo
           low-dose total-body irradiation (TBI) on day 0.

        -  Unrelated allogeneic umbilical cord blood transplantation (UCBT): After completion of
           TBI, patients undergo 1 or 2 unrelated allogeneic UCBTs on day 0.

        -  Post-transplant immunosuppression: Patients receive oral or IV cyclosporine daily
           beginning on day -3 and continuing until day 180 and oral or IV mycophenolate mofetil
           twice daily on days 0-30.

      Patients are followed periodically for 1 year after transplantation.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Survived 100 Days or Longer</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Acute Graft Versus Host Disease</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Conditioning therapy followed by TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following hematologic malignancies:

               -  Acute myeloid leukemia (AML) with or without history of myelodysplastic
                  syndromes, meeting 1 of the following criteria:

                    -  In first complete remission (CR-1) with unfavorable cytogenetics and/or
                       achieved CR-1 after ≥ 1 course of induction therapy

                    -  Secondary or treatment-related AML

                    -  In second or further complete remission

                    -  Relapsed with ≤ 20% blasts in the bone marrow AND no circulating blasts

               -  Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:

                    -  In CR-1 with unfavorable cytogenetics or elevated WBC at presentation OR
                       failed to achieve CR-1 after ≥ 4 weeks of induction therapy

                    -  In second or further complete remission

                    -  Relapsed with ≤ 20% blasts in the bone marrow AND no circulating blasts

               -  Other acute leukemic variants allowed at the discretion of the principal
                  investigator

               -  Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

                    -  In first chronic phase AND refractory to or unable to tolerate imatinib
                       mesylate

                    -  In second or further chronic phase

                    -  In first or second accelerated phase

               -  Myelodysplastic syndromes with intermediate 2- or high-risk International
                  Prognosis Scoring System (IPSS) score, including any of the following:

                    -  Refractory anemia

                    -  Refractory anemia with excess blasts

                    -  Chronic myelomonocytic leukemia

               -  Myeloproliferative disorders with poor prognosis, including any of the following:

                    -  Myelofibrosis with myeloid metaplasia

                         -  No ≥ grade 3 myelofibrosis

                    -  Atypical CML

                    -  Juvenile myelomonocytic leukemia

               -  Other clonal hemopathies with an accepted poor prognosis

               -  Multiple myeloma with chromosome 13 abnormalities and/or progression after prior
                  autologous bone marrow transplantation (BMT)

               -  Chronic lymphocytic leukemia, meeting 1 of the following criteria:

                    -  Primary refractory OR relapsed and refractory disease (less than partial
                       remission)

                    -  Relapsed twice on or after prior chemotherapy

               -  Lymphoma, meeting both of the following criteria:

                    -  Hodgkin's or non-Hodgkin's lymphoma in &gt; CR-1 OR failed primary induction

                    -  Chemosensitive disease, defined as &gt; 50% reduction in mass size after the
                       most recent chemotherapy

          -  Must meet ≥ 1 of the following criteria:

               -  Over 45 years of age

               -  Has undergone prior autologous or allogeneic BMT

               -  Charlson^ comorbidity score ≥ 2

          -  Must have a high degree of tumor control (salvage therapy allowed)

          -  At high risk for treatment-related mortality with a myeloablative conditioning regimen

          -  No massive splenomegaly

               -  Patients may become eligible after splenectomy or radiotherapy to the spleen

          -  No 5/6 or 6/6 HLA-matched related donor available

          -  No well-matched (i.e., ≥ 9/10 HLA match by high-resolution typing) unrelated donor
             available

        PATIENT CHARACTERISTICS:

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  Transaminases ≤ 4 times ULN (unless due to underlying disease)

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Cardiovascular

          -  Ejection fraction ≥ 30%

        Pulmonary

          -  DCLO ≥ 35%

        Other

          -  Negative pregnancy test

          -  No uncontrolled viral, bacterial, or fungal infection

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

        Radiotherapy

          -  See Disease Characteristics

        Other

          -  At least 3 months since prior immunosuppressive therapy

          -  At least 10 days since prior salvage therapy for patients not in at least morphologic
             or radiologic complete remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon L. Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>May 18, 2016</results_first_submitted>
  <results_first_submitted_qc>May 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conditioning Therapy Followed by TBI</title>
          <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
graft-versus-tumor prophylaxis therapy
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conditioning Therapy Followed by TBI</title>
          <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
graft-versus-tumor prophylaxis therapy
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
radiation therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Survived 100 Days or Longer</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Therapy Followed by TBI</title>
            <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
graft-versus-tumor prophylaxis therapy
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived 100 Days or Longer</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Acute Graft Versus Host Disease</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Therapy Followed by TBI</title>
            <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
graft-versus-tumor prophylaxis therapy
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Acute Graft Versus Host Disease</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Conditioning Therapy Followed by TBI</title>
          <description>Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
graft-versus-tumor prophylaxis therapy
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>relapsed transplant resulting in death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Post-transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Syndrome of Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gordon L. Phillips</name_or_title>
      <organization>Wake Forest</organization>
      <phone>604.875.4111 ext 67806</phone>
      <email>gophilli@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

